Posted by Michael Wonder on 22 Nov 2021
Vertex announces reimbursement agreement in Spain for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat people with cystic fibrosis 12 years and older with at least one F508del mutation in the CFTR gene
19 November 2021 - With this reimbursement agreement approximately 700 people with cystic fibrosis now have access to a CFTR modulator therapy for the first time.
Vertex Pharmaceuticals today announced that the Spanish government has approved terms for the national reimbursement of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis for eligible patients.
